ArticleJournal of translational medicine2026
Decoding the tumor microenvironment remodeling orchestrated by CLEC3B+ inflammatory cancer-associated fibroblasts in lung adenocarcinoma immunotherapy: elucidation from pan-cancer spatially single-cell transcriptomics landscape.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe heterogeneity of cancer-associated fibroblasts (CAFs) would possibly influence reaction to immune checkpoint inhibitor (ICI) therapy. However, limited researches investigated inflammatory CAFs (iCAFs) in ICI therapy using pan-cancer single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics RNA sequencing (stRNA-seq) analysis.
methodsWe performed pan-cancer scRNA-seq and stRNA-seq analyses to investigate CLEC3B+ iCAFs, exploring its spatial distribution characteristics. The pan-cancer scRNA-seq and RNA-seq data are incorporated to develop the Inflammatory CAF Signature (ICS), which predicts ICI response based on iCAF marker genes and machine learning techniques. Comprehensive scRNA-seq analysis, with in vivo and in vitro experiments, investigates the mechanisms by which CLEC3B+ iCAFs influence ICI efficacy.
resultsThe ICS model performs well in predicting ICI response in pan-cancer patients. A higher proportion of total iCAFs is observed in ICI non-responders in pan-cancer landscape and lung adenocarcinoma (LUAD). Cellular communication and stRNA-seq analyses confirm that intercellular interactions and cell-to-cell distances between iCAFs and CD8+ Tex cells impact ICI efficacy. A critical functional heterogeneity within iCAFs modulated by CLEC3B is revealed, while functional experiments confirm that downregulation of CLEC3B on CAFs drives CD8+ T cells toward a dysfunctional state in LUAD. CLEC3B activates JAK2–STAT3 pathway by inhibiting SOCS3 deubiquitylation, enhancing the immunostimulatory effects of CAFs. In a subcutaneously tumor grafted mouse model, combining CLEC3B overexpression with ICI treatment achieves optimal efficacy in LUAD.
conclusionOur study provides ICS model as an outperforming approach for patient selection of ICI, and advances our understanding of CAF biology and suggests potential therapeutic strategies for upregulating CLEC3B in CAFs in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.